drugset
drugset / Trial / NCT02798120

P3 Long Term Safety Study of Once Daily SB204 in Acne

NCT02798120 ↗

Phase 3 Completed 601 enrolled Novan, Inc. Chiltern International Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.

Timeline

Start
2016-05-12
Primary completion
2017-04
Completion
2017-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject BERDAZIMER SODIUM Small molecule 4 % Topical

Indications

acne